SEC Tracker
Get the app
VCEL · XBRL financial data

Vericel financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (VCEL's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue45,58164,996*51,28152,66257,90575,376*52,59863,24067,50392,918*68,42577,457
Revenue from contracts with customers45,58164,996*51,28152,66257,90575,376*52,59863,24067,50392,918*68,42577,457
Cost of goods and services sold14,97316,489*15,92716,06116,25216,877*16,32516,62717,91819,790*19,15921,055
Gross profit30,60848,507*35,35436,60141,65358,499*36,27346,61349,58573,128*49,26656,402
Research and development5,6764,901*6,4187,3636,0934,923*7,2616,7316,3187,253*8,1047,493
Selling, general and administrative29,98930,875*34,40035,26938,02535,097*41,80441,91139,81743,460*49,22648,475
General and administrative—year only14,96715,41116,24414,027*19,00119,61518,61719,557*22,680—
Total operating expenses35,66535,776*40,81842,63244,11840,020*49,06548,64246,13550,713*57,33055,968
Operating income (loss)(5,057)12,731*(5,464)(6,031)(2,465)18,479*(12,792)(2,029)3,45022,415*(8,064)434
Interest income1,2621,436*1,7621,5101,5781,560*1,6571,6571,8081,885*1,8511,954
Interest expense150156*153153154154*153157158162*160160
Other income (expense)(1)82*(7)(8)14070*42(24)(26)(36)*71(22)
Income tax expense (benefit)(286)1,100*——0148*———year only——
Net income (loss)(3,660)12,993*(3,862)(4,682)(901)19,807*(11,246)(553)5,07423,243*(6,302)2,206
Earnings per share, basic USD per share(0.08)0.27*(0.08)(0.10)(0.02)0.40*(0.23)(0.01)0.100.46*(0.12)0.04
Earnings per share, diluted USD per share(0.08)0.27*(0.08)(0.10)(0.02)—(0.23)(0.01)0.10—(0.12)0.04
Weighted average shares, basic thousands of shares47,64947,747*48,14148,68649,08549,471*49,90550,36850,48950,589*50,77351,075
Weighted average shares, diluted thousands of shares47,64947,747*48,14148,68649,08560,733*49,90550,36851,90856,355*50,77352,312

Balance sheet

CSV

Fiscal quarters (VCEL's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents60,47369,08862,93850,29153,68174,52073,49080,532100,403100,092109,295125,358
Short-term investments44,87040,46947,71052,21748,05341,69339,41236,34934,97737,40736,04537,100
Marketable securities, non-current20,23125,28329,43326,12032,89539,88043,34247,40049,66461,39565,28464,973
Accounts receivable39,72958,35649,93447,99648,47961,37552,89964,29060,42684,63472,38375,712
Inventory12,62113,08713,55714,88715,75617,37317,10616,83118,15517,56018,35118,382
Total current assets186,211205,631189,718197,386190,520212,777197,640204,577221,967247,437244,064264,730
Right-of-use asset73,29473,46273,68273,02071,56170,09868,71667,39866,08764,77463,40962,014
Total assets318,125353,657356,661376,839390,405432,722424,587435,608453,274487,969485,627502,866
Accounts payable15,05122,34719,43225,21620,88423,84816,75112,85715,33515,82819,00920,614
Accrued liabilities13,62817,21511,02612,85614,34317,06511,41814,40416,28619,23613,96717,644
Total current liabilities35,94645,74936,47043,86341,34650,28639,44841,13245,58249,14947,15552,532
Lease liability, non-current77,73481,85686,14189,80191,34489,59387,80486,01184,16182,28480,36278,379
Total liabilities113,745127,705122,765133,862132,933140,755129,100128,799131,416133,329129,396132,825
Accumulated deficit(416,170)(403,177)(407,039)(411,721)(412,622)(392,815)(404,061)(404,614)(399,540)(376,297)(382,599)(380,393)
Total stockholders' equity204,380225,952233,896242,977257,472291,967295,487306,809321,858354,640356,231370,041
Total liabilities and equity318,125353,657356,661376,839390,405432,722424,587435,608453,274487,969485,627502,866
Common shares outstanding (cover page) thousands of shares47,72548,29048,60249,03049,35849,97050,34350,46050,57450,76351,06851,207

Cash flows

CSV

Fiscal quarters (VCEL's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(3,660)12,993*(3,862)(4,682)(901)19,807*(11,246)(553)5,07423,243*(6,302)2,206
Stock-based compensation7,924*6,909*9,8349,520*9,224*7,917*11,50510,140*8,699*8,423*11,2949,083*
Depreciation and amortization1,154*1,149*1,3781,323*1,326*1,477*2,6862,826*2,944*3,088*3,2673,620*
Net cash from operating activities7,169*10,086*7,20218,535*10,184*22,242*6,6008,214*22,082*15,014*16,38316,191*
Purchases of property and equipment6,569*7,835*14,01716,761*19,409*13,787*14,2128,133*2,630*2,187*1,2571,932*
Net cash from investing activities4,566*(8,088)*(25,452)(17,719)*(21,212)*(14,651)*(15,142)(9,028)*(3,377)*(16,390)*(4,201)(2,820)*
Proceeds from issuing common stock1,116*1,386*7,0264,434*5,795*7,261*9,4091,788*1,482*1,255*1,5632,858*
Net cash from financing activities1,009*1,307*2,1264,296*5,524*7,108*3,1981,641*1,166*1,065*(2,979)2,692*
Net change in cash12,744*3,305*(16,124)5,112*(5,504)*14,699*(5,344)827*19,871*(311)*9,20316,063*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Vericel125,35877,45716,191*51.2M— 10-QJun 30, 2026
Avadel Pharmaceuticals79,81377,46722,205*97.7M— 10-QSep 30, 2025
Recursion Pharmaceuticals549,85318,552(77,406)*622.8M6.2 quarters 10-QSep 30, 2026
Bausch Health Companies2,485,0002,941,000814,000*374.3M— 10-QSep 30, 2026
Acadia Pharmaceuticals384,985307,959100,781*172.3M— 10-QJun 30, 2026
Agios Pharmaceuticals99,64744,745(57,312)*59.7M10.8 quarters 10-QJun 30, 2026
Twist Bioscience117,436not reported1,115*62.7M— 10-QJun 30, 2026
Biocryst Pharmaceuticals154,972not reported104,342*255.5M— 10-QJun 30, 2026
Xenon Pharmaceuticals119,527not reported(95,390)*96.8M9.8 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.